STOCK TITAN
  1. Home
  2. News
  3. FDMT

4D Molecular Therapeutics Inc - FDMT STOCK NEWS

Welcome to our dedicated news page for 4D Molecular Therapeutics (Ticker: FDMT), a resource for investors and traders seeking the latest updates and insights on 4D Molecular Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect 4D Molecular Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of 4D Molecular Therapeutics's position in the market.

News
4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis
Rhea-AI Summary
4D Molecular Therapeutics announces regulatory interactions and development path for 4D-710, an aerosolized genetic medicine for cystic fibrosis lung disease. Positive clinical data, technology transfer, and pivotal trial plans revealed.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.18%
Tags
none
-
News
4DMT to Participate in Upcoming Investor Conferences
Rhea-AI Summary
4D Molecular Therapeutics (FDMT) to participate in investor conferences in March 2024, presenting at Leerink Partners Global Biopharma Conference and Barclays Annual Global Healthcare Conference. Management team to engage in fireside chats and one-on-one meetings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.15%
Tags
conferences
-
News
4DMT Reports Full Year 2023 Financial Results and Operational Highlights
Rhea-AI Summary
4D Molecular Therapeutics reported positive interim data from Phase 2 PRISM study, advancing into Phase 3 development. The company showcased clinical progress in multiple therapeutic areas, strong financial results, and strategic agreements with Astellas Pharma and Arbor Biotechnologies. 4DMT's cash position of $299 million extends operational runway into 2027.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.82%
Tags
earnings
News
4DMT Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials for Fabry Disease Cardiomyopathy at WORLDSymposium™ 2024
Rhea-AI Summary
4D Molecular Therapeutics (Nasdaq: FDMT) announces positive interim safety and efficacy data on 4D-310 for Fabry disease cardiomyopathy, showcasing improvements in cardiac function, exercise capacity, and quality of life. The therapy demonstrated efficient delivery, transgene expression, and clearance of Gb3 substrate in cardiomyocytes, with no new adverse events reported.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.72%
Tags
clinical trial
-
News
4D Molecular Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
Rhea-AI Summary
4D Molecular Therapeutics, Inc. (FDMT) announced the pricing of an upsized underwritten public offering of its common stock, with a 30-day option to purchase additional shares. The gross proceeds from the offering are expected to be approximately $300 million. The offering is expected to close on February 9, 2024, and is managed by Goldman Sachs & Co. LLC, BofA Securities, Jefferies, and Barclays. The registration statement was automatically effective upon filing on February 5, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.97%
Tags
offering
-
News
4D Molecular Therapeutics Announces Proposed Public Offering of Common Stock
Rhea-AI Summary
4D Molecular Therapeutics, Inc. (FDMT) has announced a public offering of $250.0 million of its common stock with an option for underwriters to purchase an additional $37.5 million. The offering is subject to market conditions, and the company has filed a registration statement with the SEC. The joint book-running managers for the offering are Goldman Sachs & Co. LLC, BofA Securities, Jefferies, and Barclays.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.85%
Tags
offering
News
4DMT Presents Positive Interim Data from Randomized Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 Demonstrating Favorable Tolerability & Clinical Activity in Wet AMD
Rhea-AI Summary
4D Molecular Therapeutics (Nasdaq: FDMT) announced positive interim data from the Phase 2 PRISM clinical trial evaluating intravitreal 4D-150 in wet age-related macular degeneration (wet AMD) patients with severe disease activity and a high treatment burden. The study showed that 4D-150 was well tolerated, resulting in an 89% reduction in the annualized anti-VEGF injection rate. The positive interim results enable rapid advancement towards pivotal development, with Phase 3 clinical trial initiation expected in Q1 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
News
4DMT to Host Corporate Webcast to Discuss Interim Data from Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 in Wet AMD Patients with Severe Disease Activity & High Treatment Burden
Rhea-AI Summary
4D Molecular Therapeutics (FDMT) announces a live webcast to discuss interim data from the intravitreal 4D-150 Phase 2 PRISM clinical trial in wet AMD patients with severe disease activity and high treatment burden. The company will also provide a program update on Monday, February 5, 2024. The webcast will be presented by Arshad M. Khanani, M.D., M.A., FASRS, Principal Investigator of the PRISM clinical trial. The presentation of the interim results will also be available at the Angiogenesis, Exudation, and Degeneration 2024 Conference on Saturday, February 3, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.97%
Tags
conferences clinical trial
-
News
4DMT Receives Rare Pediatric Disease Designation from FDA for Aerosolized 4D-710 for Treatment of Cystic Fibrosis Lung Disease
Rhea-AI Summary
4D Molecular Therapeutics (Nasdaq: FDMT) announced that the U.S. FDA granted Rare Pediatric Disease Designation for aerosolized 4D-710, a treatment for cystic fibrosis lung disease. Promising clinical trial results showed significant CFTR expression levels and improved quality of life for patients. The company is also planning an interim data update and pivotal trial planning update for 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.77%
Tags
none
News
TurnCare, Inc. Announces John F. Milligan, PhD, former CEO of Gilead Sciences, joins Board of Directors
Rhea-AI Summary
TurnCare, a leading medical technology and services company dedicated to advancing how hospitals manage high acuity patients, proudly announces the addition of John F. Milligan, Ph.D., investor, innovator, and former CEO of Gilead, to its Board of Directors. Dr. Milligan's expertise includes driving major acquisitions to create unique industry solutions and scaling Gilead to over $21 Billion in worldwide sales with a market cap of $85 Billion. He brings a unique and valuable perspective that will help TurnCare maximize the impact of its novel patient management technologies as it scales to more networks, hospitals, and patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.78%
Tags
management
Stock FDMT logo
4D Molecular Therapeutics Inc

Nasdaq:FDMT

FDMT Rankings

#2275 Ranked by Market Cap
#891 Ranked by Stock Gains
N/A Ranked by Dividends

FDMT Stock Data

1.35B
31.64M
3.53%
85.52%
18.72%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States
Emeryville

About FDMT

the mission of 4d molecular therapeutics is to design and develop transformative gene therapy products using our proprietary technology to create novel adeno-associated virus variants to be utilized as treatments for serious unmet medical conditions. our products are unlocking the full potential of gene therapy to treat, and potentially cure, genetic diseases. a large number of patients and diseases, who previously were not treatable by gene therapy, will be addressable by 4d products. 4d has one of the deepest and most diverse product pipelines in the gene therapy field. adeno-associated virus (aav) vectors have emerged as a favored delivery vehicle for gene therapy in the human body. they can deliver the genes for therapeutic proteins to accessible tissues in the body and are generally considered safe. several aav gene therapy products are in late-stage clinical development, and one product is approved in the eu (glybera, uniqure). however, these first-generation aav vectors have lim